Article Text

Download PDFPDF
Rituximab therapy for chronic periaortitis
  1. Federica Maritati1,
  2. Domenico Corradi2,
  3. Annibale Versari3,
  4. Massimiliano Casali3,
  5. Maria Letizia Urban1,
  6. Carlo Buzio1,
  7. Augusto Vaglio1
  1. 1Department of Clinical Medicine, Nephrology and Health Science, University Hospital of Parma, Parma, Italy
  2. 2Department of Pathology and Laboratory Medicine, University of Parma, Parma, Italy
  3. 3Nuclear Medicine Service, Santa Maria Nuova Hospital, Reggio Emilia, Italy
  1. Correspondence to Augusto Vaglio, Department of Clinical Medicine, Nephrology and Health Science, University Hospital of Parma, Via Gramsci 14, 43126 Parma, Italy; augusto.vaglio{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Chronic periaortitis (CP) is a rare condition, hallmarked by periaortic fibro-inflammatory tissue which often causes ureteral obstruction, and encompasses idiopathic retroperitoneal fibrosis and inflammatory abdominal aortic aneurysm (IAAA). CP usually responds to glucocorticoids, but some patients may be steroid-refractory or not tolerate standard glucocorticoid doses. For such cases, valid therapeutic alternatives are lacking.1 2 Combinations of prednisone and immunosuppressants (eg, cyclophosphamide, mycophenolate mofetil) are not of proven superiority to prednisone alone, and their effectiveness in refractory CP is unknown.3 4 Because B cells abundantly infiltrate CP lesions,5 and CP is often associated with autoimmune diseases,6 we used rituximab in two patients with CP, one refractory to conventional treatments, and the other with contraindications to standard-dose glucocorticoids.

Our first patient, a 49-year-old woman, was hospitalised for malaise and back pain. Abdominal CT revealed a soft-tissue-density periaortic mass suggesting CP, a diagnosis confirmed by laparoscopic biopsy (figure 1). The patient responded to prednisone (initial dose, 1 mg/kg/day), with symptom remission and reduction in CP thickness, but relapsed with back pain and CP enlargement when the prednisone dose was 5 mg/day (8 months after treatment initiation). …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.